Investor Information
| Stéphane Bette, Co founder and Deputy CEO |
Pierre Jérôme, Co founder, CEO & Chairman |
Dear Shareholders,
Our co-founders, Pierre Jérôme and Stéphane Bette, provide direct answers to key shareholder questions about SpineGuard’s strategy, financial situation, and future prospects. View the management message
Read the latest Financial News
Stock Information
Stock exchange information
- ISIN code: FR0011464452
- Stock Quote: ALSGD
- Number of shares: 62.227.957
- Sector: Medical technologies
- Principal Index: Alternext All-share
- Exchange: Euronext-Growth
- Place of listing: Euronext Paris (France)
- Eligibility to French PEA/SRD: Yes/No
- Eligibility French PEA-PME: Yes
Financial agenda
- January 19, 2026: 2025 Full-Year Sales
- April 8, 2026: 2025 Full-Year Results
- April 8, 2026: 2026 First-Quarter Sales
- May 26, 2026: Annual Shareholders Meeting (1st summoning)
- June 10, 2026: Annual Shareholders Meeting (2nd summoning if required)
- July 8, 2026: 2026 First-Half Sales
- September 9, 2026: 2026 First-Half Results
- October 8, 2026: 2026 Third-Quarter Sales
Analysts
- Morning Note – 5th December 2025
- Morning Note – 10th October 2025
- Morning Note – 11th September 2025
- Morning Note – 17th July 2025
- Morning Note – 10th July 2025
- Morning Note – 16th April 2025
- Morning Note – 10th April 2025
- Morning Note – 11th February 2025
- Morning Note – 13th January 2025
- Morning Note – 7th January 2025
- Biostrategic Research: Lionel Labourdette
Others
- Liquidity contract: Tradition Securities And Futures (TSAF)
- Auditors: Grant Thornton
- Listing Sponsor: Swiss Life Banque Privée
Shareholders structure
(June 25th, 2025)
Stock quotes
- To check the stock quote in real time, click here.
Vous avez des questions ?